Moderna's Effective COVID Vaccine

Moderna's Effective COVID Vaccine

over 3 years ago1 min

Moderna doesn’t want to get into a drug-measuring contest or anything, but the biotech company did announce on Monday that its vaccine is even more effective than Pfizer’s 💉

What does this mean?

This announcement makes Moderna the second US company to announce late-stage trial data that beat expectations. Next stop: approval from US and European regulators, which Moderna’s said it’ll officially request in the next few weeks ✅ From there, the biotech has set its sights high: it’s expecting to ship 20 million doses of the dual-dose vaccine to the US by the end of this year, and between 500 million and a billion doses globally by the end of 2021.

Small groups of countries have supply deals with Pfizer and Moderna for Covid-19 vaccine

Why should I care?

A major advantage of Moderna’s vaccine isn’t just its 94.5% effectiveness to Pfizer’s 90%: it’s that it lasts for 30 days at refrigerator temperatures, compared to Pfizer’s five. That could make distribution of the drug simpler and cheaper, since it won’t need the ultra-cold storage that Pfizer’s will 🧊 Still, with demand for a vaccine so much higher than any one drugmaker can meet in the near term, they’ll both have their time to shine. That’s certainly true in China, where vaccinations are already underway, as well as in Russia, whose Sputnik-V coronavirus vaccine – which was licensed for domestic use in August – is reportedly 92% effective.

Moderna shares jump along with broader market
Source: The Wall Street Journal

A vaccine is considered the single best way to get the global economic recovery back on track, but there’s already the odd bright spot if you look closely enough ☀️ Here’s one: Chinese industrial production and retail consumption data jumped by the most this year in October. That’s a good thing for European and American companies too: it means Chinese shoppers will be more than happy to keep buying their products.

Vaccine gif
Finimize

BECOME A SMARTER INVESTOR

All the daily investing news and insights you need in one subscription.

Disclaimer: These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment advisor.

/3 Your free quarterly content is about to expire. Uncover the biggest trends and opportunities. Subscribe now for 50%. Cancel anytime.

Finimize
© Finimize Ltd. 2023. 10328011. 280 Bishopsgate, London, EC2M 4AG